Physician profile
Peter Nowotarski
NPI 1619953783
$508,950.75
in general payments reported to CMS, 2019-2025
14 companies · $117K in 2025
The $117K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $65K · 2021: $68K · 2022: $73K · 2023: $81K · 2024: $64K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $263K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $262,552.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Products, INC. | $506,562.92 | 2019-2025 | Expert Nail |
| Medical Device Business Services, INC. | $1,669.82 | 2019 | |
| Depuy Synthes Sales INC. | $280.95 | 2019-2021 | |
| Smith+Nephew, INC. | $161.59 | 2019-2020 | |
| Radius Health, INC. | $59.93 | 2019-2022 | |
| Alpha Orthopedic Systems | $46.89 | 2019 | |
| Bioventus LLC | $32.14 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $26.38 | 2022 | |
| Ucb, INC. | $24.73 | 2019 | |
| Axogen | $24.40 | 2019 | |
| Si-Bone, INC. | $19.66 | 2020 | |
| Amgen INC. | $14.83 | 2022 | |
| Abbvie INC. | $14.80 | 2021 | |
| Allergan, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Nowotarski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.